Paraoxonase-1 (PON1) Status in Pancreatic Cancer: Relation to Clinical Parameters (pancreaticcancer/paraoxonase1(PON1)polymorphisms/PON1arylesterase/lactonaseactivities/ malnutrition)

Le résumé fourni par la source

Human paraoxonase 1 (PON1) has been shown to decrease the level of systemic oxidative stress, which is thought to contribute to cancer devel- opment. The aim of this study was to examine the interrelationships between PON1 status and some clinical characteristics in patients with pancreatic cancer (PC). A group of 73 consecutive patients with PC (stage II-IV) and 73 control subjects were exam- ined. Laboratory studies included five polymor - phisms of the PON1 gene (L55M, Q192R, -108C/T, -126C/T, and -162A/G), PON1 arylesterase (PON1-A) and lactonase (PON1-L) activities, as well as some markers of protein metabolism, insulin resistance, and oxidative stress. In comparison with the control group, no difference in the distribution of the PON1 polymorphisms was found in cancer patients, both arylesterase and lactonase activities being signifi- cantly lower (-33, -47 %, respectively, both P < 0.001).

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.